提醒成功

搜索
产品规范 | |
---|---|
Type | In Vivo - Reseach Grade Antibody |
Host | CHO cells |
catalog# | B00046 |
Application | Flow cytometry, animal model study |
Aliases | CC chemokine receptor type 4, CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099, K5-5, C-C motif chemokine receptor 4 |
Size/Concentration | 1mg/5mg/20mg |
Isotype | Human IgG1 kappa |
Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Human CCR4 |
Formulation | PBS, pH 7.4 |
Description |
---|
Mogamulizumab Biosimilar uses the same protein sequences as the therapeutic antibody mogamulizumab. Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Mogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity. |
Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody B00046
规格:
- 1mg
- 5mg
- 20mg
数量:
-
+
说明书:


¥3250
-
咨询
-
收藏

